Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.

The U.K. created the CPSA to set safety standards for non-surgical cosmetic treatments and improve patient protection.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

A new method effectively analyzes Finasteride and its impurities, even under stress conditions.

Combining sodium valproate with other epilepsy drugs increases ammonia levels and side effects.

Hair root sheaths can be used to accurately analyze genetic markers.

New butyric acid prodrugs show promise for cancer treatment, anemia management, and protecting hair from chemotherapy damage.

A reliable method was developed to measure Finasteride and Tadalafil in rat blood.

A new patch can deliver stable antibodies over time for potential HIV treatment.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

A rare case of Cushing syndrome was successfully treated with one-sided adrenal gland removal, suggesting personalized treatment is important.

Presurgical models can effectively and affordably screen cancer prevention agents.

Platelet-rich plasma injections can effectively treat alopecia areata barbae.

Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.

Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.

The syringe method is better for preparing platelet-rich plasma.

Valproic acid treatment may cause hair loss due to reduced biotinidase activity.

Big chain pharmacies in Pennsylvania charge significantly more for generic BPH medications than independent pharmacies, but independent pharmacies have more regional price variation.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

The M-type is the most common form of male hair loss, and the BASP-classification is easy for different medical professionals to use.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.

A 70-year-old woman with bronchiectasis developed a rare immune disease due to a bacterial infection, requiring a difficult balance of treatments.

PAD is common but often missed, needing lifestyle changes and medication for better outcomes.

BPH treatments can cause sexual side effects affecting quality of life.

Large prostate patients more likely to have hair loss.

A certain gene variation can affect protein production and is linked to male pattern baldness.